367 related articles for article (PubMed ID: 26396249)
21. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA
Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029
[TBL] [Abstract][Full Text] [Related]
22. Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.
Lue JK; Prabhu SA; Liu Y; Gonzalez Y; Verma A; Mundi PS; Abshiru N; Camarillo JM; Mehta S; Chen EI; Qiao C; Nandakumar R; Cremers S; Kelleher NL; Elemento O; Amengual JE
Clin Cancer Res; 2019 Sep; 25(17):5271-5283. PubMed ID: 30979734
[TBL] [Abstract][Full Text] [Related]
23. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.
Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM
Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222
[TBL] [Abstract][Full Text] [Related]
24. Epigenetically maintained SW13+ and SW13- subtypes have different oncogenic potential and convert with HDAC1 inhibition.
Davis MR; Daggett JJ; Pascual AS; Lam JM; Leyva KJ; Cooper KE; Hull EE
BMC Cancer; 2016 May; 16():316. PubMed ID: 27188282
[TBL] [Abstract][Full Text] [Related]
25. Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma.
Lanzi C; Favini E; Dal Bo L; Tortoreto M; Arrighetti N; Zaffaroni N; Cassinelli G
J Exp Clin Cancer Res; 2021 Dec; 40(1):381. PubMed ID: 34857011
[TBL] [Abstract][Full Text] [Related]
26. Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells.
Grinshtein N; Rioseco CC; Marcellus R; Uehling D; Aman A; Lun X; Muto O; Podmore L; Lever J; Shen Y; Blough MD; Cairncross GJ; Robbins SM; Jones SJ; Marra MA; Al-Awar R; Senger DL; Kaplan DR
Oncotarget; 2016 Sep; 7(37):59360-59376. PubMed ID: 27449082
[TBL] [Abstract][Full Text] [Related]
27. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
[TBL] [Abstract][Full Text] [Related]
28. Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma.
Zhao L; Okhovat JP; Hong EK; Kim YH; Wood GS
Neoplasia; 2019 Jan; 21(1):82-92. PubMed ID: 30529073
[TBL] [Abstract][Full Text] [Related]
29. JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.
Arts J; King P; Mariën A; Floren W; Beliën A; Janssen L; Pilatte I; Roux B; Decrane L; Gilissen R; Hickson I; Vreys V; Cox E; Bol K; Talloen W; Goris I; Andries L; Du Jardin M; Janicot M; Page M; van Emelen K; Angibaud P
Clin Cancer Res; 2009 Nov; 15(22):6841-51. PubMed ID: 19861438
[TBL] [Abstract][Full Text] [Related]
30. The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells.
Kiweler N; Brill B; Wirth M; Breuksch I; Laguna T; Dietrich C; Strand S; Schneider G; Groner B; Butter F; Heinzel T; Brenner W; Krämer OH
Arch Toxicol; 2018 Jul; 92(7):2227-2243. PubMed ID: 29845424
[TBL] [Abstract][Full Text] [Related]
31. Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo.
Zuco V; De Cesare M; Cincinelli R; Nannei R; Pisano C; Zaffaroni N; Zunino F
PLoS One; 2011; 6(12):e29085. PubMed ID: 22194993
[TBL] [Abstract][Full Text] [Related]
32. Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells.
Chiba T; Yokosuka O; Fukai K; Kojima H; Tada M; Arai M; Imazeki F; Saisho H
Oncology; 2004; 66(6):481-91. PubMed ID: 15452378
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
Catalano MG; Pugliese M; Gargantini E; Grange C; Bussolati B; Asioli S; Bosco O; Poli R; Compagnone A; Bandino A; Mainini F; Fortunati N; Boccuzzi G
Int J Cancer; 2012 Feb; 130(3):694-704. PubMed ID: 21400508
[TBL] [Abstract][Full Text] [Related]
34. YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.
Shindoh N; Mori M; Terada Y; Oda K; Amino N; Kita A; Taniguchi M; Sohda KY; Nagai K; Sowa Y; Masuoka Y; Orita M; Sasamata M; Matsushime H; Furuichi K; Sakai T
Int J Oncol; 2008 Mar; 32(3):545-55. PubMed ID: 18292931
[TBL] [Abstract][Full Text] [Related]
35. VEGF-mediated cell survival in non-small-cell lung cancer: implications for epigenetic targeting of VEGF receptors as a therapeutic approach.
Barr MP; O'Byrne KJ; Al-Sarraf N; Gray SG
Epigenomics; 2015; 7(6):897-910. PubMed ID: 26479311
[TBL] [Abstract][Full Text] [Related]
36. SMARCB1/INI1 genetic inactivation is responsible for tumorigenic properties of epithelioid sarcoma cell line VAESBJ.
Brenca M; Rossi S; Lorenzetto E; Piccinin E; Piccinin S; Rossi FM; Giuliano A; Dei Tos AP; Maestro R; Modena P
Mol Cancer Ther; 2013 Jun; 12(6):1060-72. PubMed ID: 23576573
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer.
Li ZH; Zhang XB; Han XQ; Feng CR; Wang FS; Wang PG; Shen J; Shi YK
Oncol Rep; 2013 Jul; 30(1):499-505. PubMed ID: 23624828
[TBL] [Abstract][Full Text] [Related]
38. A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.
Yang YT; Balch C; Kulp SK; Mand MR; Nephew KP; Chen CS
Neoplasia; 2009 Jun; 11(6):552-63, 3 p following 563. PubMed ID: 19484144
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53.
Mrakovcic M; Bohner L; Hanisch M; Fröhlich LF
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544838
[TBL] [Abstract][Full Text] [Related]
40. Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft.
Tarasenko N; Nudelman A; Rozic G; Cutts SM; Rephaeli A
Invest New Drugs; 2017 Aug; 35(4):412-426. PubMed ID: 28315153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]